Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00167817 · ClinicalTrials.gov registry record · Phase 4
Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
A Phase 4 study, sponsored by Veterans Medical Research Foundation.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT00167817 is a Phase 4 study that has completed, run by Veterans Medical Research Foundation. The registered enrollment target is 15 participants.
The verdict
NCT00167817, a Phase 4 study, has completed, sponsored by Veterans Medical Research Foundation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
Patients with schizophrenia are much more likely to be engaged in smoking and other addictive behaviors, possibly related to biochemical abnormalities in the reward center of the brain. The primary purpose of the present study is to investigate whether switching patients with schizophrenia to a new atypical antipsychotic, aripiprazole, a drug with a novel mechanism of action, will have an impact on smoking behavior.
Interventions
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2003-07 |
| Est. Completion | 2005-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00167817
The ClinicalTrials.gov registry entry for NCT00167817 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veterans Medical Research Foundation, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00167817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00167817 about?
NCT00167817 is a clinical study titled "Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study". Patients with schizophrenia are much more likely to be engaged in smoking and other addictive behaviors, possibly related to biochemical abnormalities in the reward center of the brain. The primary purpose of the present study is to investigate whether switching patients with schizophrenia to a new ...
What is the current status of trial NCT00167817?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2003-07. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00167817?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00167817?
This trial is sponsored by Veterans Medical Research Foundation, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.